NuCana (NASDAQ:NCNA) Releases Earnings Results

NuCana (NASDAQ:NCNA) issued its quarterly earnings data on Thursday. The company reported ($1.25) EPS for the quarter, topping analysts’ consensus estimates of ($2.64) by $1.39, Zacks reports.

NuCana Stock Performance

Shares of NASDAQ NCNA traded up $0.20 during midday trading on Friday, reaching $2.18. 130,323 shares of the company’s stock were exchanged, compared to its average volume of 31,768. NuCana has a 52-week low of $1.33 and a 52-week high of $40.00. The stock has a market capitalization of $9.07 million, a PE ratio of -0.73 and a beta of 2.17. The business’s fifty day moving average price is $1.93 and its two-hundred day moving average price is $2.79.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of NuCana in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

About NuCana

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.